ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

Post author:admERY
Post published:July 20, 2015
Post category:Newsroom

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

You Might Also Like

ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020

ERYTECH to Present at the 2021 BIO CEO & Investor Conference